STOCK TITAN

Axogen (AXGN) Stock News, May 6, 2020

AXGN NASDAQ

Axogen, Inc. develops and commercializes surgical solutions for peripheral nerve regeneration and repair. The company’s recurring updates center on its portfolio for restoration of peripheral nerve function, including Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.

Company news also includes quarterly and annual financial results, revenue guidance, gross margin and cash metrics, investor-conference participation, FDA-related developments for Avance, and capital-structure actions involving common stock. These updates connect operating performance with Axogen’s commercial activity in nerve repair products across its target markets.

Rhea-AI Summary

Axogen, Inc. (NASDAQ: AXGN) reported Q1 2020 net revenue of $24.3 million, a 4% increase from Q1 2019. However, gross margin declined to 80.1%. The company posted a net loss of $8.2 million or $0.21 per share, compared to a loss of $9.5 million in the same quarter last year. Active accounts rose by 13% to 825. Due to COVID-19, the company suspended its 2020 guidance, foreseeing reduced revenues. Additionally, Axogen returned a $7.8 million PPP loan amid changing eligibility standards. A class action lawsuit was dismissed, and cost-cutting measures were implemented.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.87%
Tags

FAQ

What is the current stock price of Axogen (AXGN)?

Axogen (AXGN) last closed at $56.95.

What is the market cap of Axogen (AXGN)?

The market cap of Axogen (AXGN) is approximately $3.4B.